Drug Trial Radar · NCT06481488
A Study of E2086 in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Jan 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Jun 25, 2024
Primary completion
Dec 13, 2024
Study completion Dec 13, 2024
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Jul 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to evaluate the safety and tolerability following multiple ascending doses of E2086 in healthy adult participants.
Conditions
- Healthy Volunteers
Interventions
E2086Drug
E2086 tablets.
PlaceboDrug
E2086 matched placebo tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Day 10
- Part A: Number of Participants With Serious Adverse Events (SAEs)Time frame: Day 10
- Part A: Number of Participants With Clinically Significant Abnormal Laboratory ParametersTime frame: Day 10
- Part A: Number of Participants With Clinically Significant Abnormal Vital Signs ValuesTime frame: Day 10
- Part A: Number of Participants With Clinically Significant Abnormal Electrocardiograms (ECGs) FindingsTime frame: Day 10
- Part A: Number of Participants With Clinically Significant Abnormal Electroencephalogram (EEG) FindingsTime frame: Day 8
- Part A: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-suicide Severity Rating Scale (C-SSRS)Time frame: Day 10
- Part B: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRSTime frame: Day 7
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Parexel International
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.